526139 — Transgene Biotek Income Statement
0.000.00%
Last trade - 00:00- IN₹326.57m
- IN₹468.92m
- IN₹2.61m
Annual income statement for Transgene Biotek, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | R2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IAS | IAS | IAS | IAS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 1.7 | 0.867 | 0.551 | 2.35 | 2.61 |
| Cost of Revenue | |||||
| Gross Profit | 1.09 | 1.33 | -0.112 | 2.34 | 2.61 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 106 | 105 | 60.6 | 9.44 | 14.8 |
| Operating Profit | -104 | -104 | -60 | -7.09 | -12.2 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -104 | -104 | -60.1 | -6.55 | -6.76 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -104 | -104 | -60.1 | -6.55 | -6.76 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -104 | -104 | -60.1 | -6.55 | -6.76 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -104 | -104 | -60.1 | -6.55 | -6.76 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.38 | -1.37 | -0.793 | -0.087 | -0.09 |